PP
BCRX icon

Pingora Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pingora Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$1.56K – 189
2025
Q4 		$1.56K Hold
200
– – ﹤0.01% 201
2025
Q3 		$1.52K Hold
200
– – ﹤0.01% 197
2025
Q2 		$1.79K Hold
200
– – ﹤0.01% 201
2025
Q1 		$1.5K Hold
200
– – ﹤0.01% 204
2024
Q4 		$1.5K Hold
200
– – ﹤0.01% 221
2024
Q3 		$1.52K Hold
200
– – ﹤0.01% 221
2024
Q2 		$1.24K Hold
200
– – ﹤0.01% 231
2024
Q1 		$1.02K Hold
200
– – ﹤0.01% 254
2023
Q4 		$1.2K Buy
+200
New +$1.16K ﹤0.01% 158

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Pingora Partners's BCRX Position: Q1 2026 in Review

Pingora Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 200 shares — an estimated $1.56K sold.

Pingora Partners first reported a position in BCRX in Q4 2023 and held it in 9 quarters. The position peaked at $1.79K in Q2 2025. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Pingora Partners reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Pingora Partners sold 200 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $1.56K.
  • Pingora Partners first reported a position in BioCryst Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • Pingora Partners's BioCryst Pharmaceuticals position peaked at $1.79K in Q2 2025.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Pingora Partners's 13F filing for Q1 2026, filed 15 May 2026.